The U.S. Department of Health and Human Services has authorized testing for fentanyl in federally regulated occupations, including truck drivers, through both urine and oral fluid drug panels effective July 2024.

Leading oncology CMOs express concern over the overwhelming volume of practice-changing data emerging from major conferences, making it increasingly difficult for physicians to stay current with optimal treatment approaches.

A cross-sectional study of 4,086 adults reveals that moderately high dietary calcium intake (770-1151.5 mg) is associated with increased eczema prevalence, particularly affecting postmenopausal women and non-Hispanic White individuals.

The FDA has authorized marketing of 20 Zyn nicotine pouch products, marking the first-ever approval in this category after extensive scientific review showing lower health risks compared to traditional tobacco products.

A comprehensive Danish study of over 48,000 patients reveals significantly elevated antimicrobial use in multiple B-cell cancer types, particularly CLL, MM, MZL, and LPL, up to 10 years before diagnosis.

Capivasertib combined with fulvestrant demonstrates significant progression-free survival benefit in patients with AKT pathway-altered metastatic breast cancer, showing a median PFS of 7.3 months versus 3.1 months with placebo.

Laminar Pharma's LAM561, combined with standard chemoradiotherapy, demonstrates significant progression-free survival improvement in MGMT-methylated glioblastoma patients, with PFS extending to 86.4 weeks versus 54.7 weeks in the placebo group.

The Lung Ambition Alliance, a partnership of major healthcare organizations, aims to double five-year lung cancer survival rates by 2025 through improved screening, innovative medicines, and enhanced quality of care.

Pi-Cardia's ShortCut device receives FDA clearance to reduce coronary obstruction risk during valve-in-valve transcatheter aortic valve replacement (TAVR).

The combination of sonrotoclax and dexamethasone demonstrated a 75% overall response rate in heavily pretreated patients with relapsed/refractory multiple myeloma.

Toleranzia has submitted a clinical trial application (CTA) for TOL2, a drug candidate targeting the underlying cause of myasthenia gravis.

PDS Biotechnology's IMMUNOCERV trial shows an 84.4% overall survival rate at 36 months for advanced cervical cancer patients treated with PDS0101 and chemoradiation.

Elucid's PlaqueIQ, an AI-driven image analysis software, has secured FDA 510(k) clearance for detecting arterial plaque, a key indicator of cardiovascular disease (CVD).

Sun Pharmaceutical Industries has received approval from the CDSCO panel to conduct a Phase III clinical trial of Aflibercept injection for neovascular age-related macular degeneration.

Rhythm Biosciences' second-generation ColoSTAT kit demonstrated superior analytical results compared to its predecessor in preliminary testing using 200 patient serum samples.

Post-mortem brain tissue study reveals anti-amyloid Alzheimer's drugs extensively bind to blood vessels in individuals with Down syndrome, raising safety concerns.

uniQure's AMT-130 demonstrated a statistically significant, dose-dependent slowing of Huntington's disease progression in Phase I/II trials, as measured by the cUHDRS.

Ionis Pharmaceuticals reports positive progress with WAINUA launch and regulatory approvals in the UK and Europe for ATTRv-PN treatment.

Soleno Therapeutics' New Drug Application (NDA) for DCCR (diazoxide choline) for Prader-Willi syndrome (PWS) has been accepted by the FDA and granted Priority Review.

Adicet Bio broadens its ADI-001 Phase 1 trial to include six autoimmune indications, with preliminary lupus nephritis data anticipated in the first half of 2025.